See the DrugPatentWatch profile for Qelbree
Qelbree, a medication for ADHD, received FDA approval to improve symptom control in adults and children. The drug targets a specific mechanism to address the condition [1].
What is Qelbree and how does it work for ADHD?
Qelbree is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged 6 years and older [1]. It works by modulating a specific neurotransmitter pathway in the brain believed to be involved in ADHD symptoms. Specifically, Qelbree is a novel selective norepinephrine reuptake inhibitor (SNRI) that increases the levels of norepinephrine in the brain [1]. Norepinephrine is a neurotransmitter that plays a role in attention, focus, and impulse control [1].
How long does it take for Qelbree to work?
Clinical trials have shown that Qelbree begins to improve ADHD symptoms within a certain timeframe, with significant effects observed over several weeks of treatment. Patients typically start to notice improvements in their core ADHD symptoms, such as inattention and hyperactivity/impulsivity, within the initial weeks of therapy. The full therapeutic benefit may take longer to realize as the medication is titrated to the optimal dose for each individual [1].
What are the potential side effects of Qelbree?
Like all medications, Qelbree can cause side effects. The most common side effects reported in clinical studies include insomnia, decreased appetite, fatigue, nausea, vomiting, and somnolence [1]. Some patients may experience mood changes, including depression or suicidal thoughts, though this is less common. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].
When does Qelbree's patent expire?
Information regarding the specific patent expiry dates for Qelbree is available through resources that track pharmaceutical patents. These patents provide market exclusivity for the drug's manufacturer. DrugPatentWatch.com is a resource that provides detailed information on drug patents and their expiration timelines, which can be crucial for understanding when generic competition might emerge [2].
Who manufactures Qelbree?
Qelbree is manufactured by the pharmaceutical company Supernus Pharmaceuticals, Inc. [1]. Supernus Pharmaceuticals is dedicated to developing and commercializing products for central nervous system (CNS) conditions [1].